Albireo, an Ipsen Company
5 clinical trials · Sponsor
◉ Watch Albireo, an Ipsen Company
| Record | Firm | Date |
|---|---|---|
| Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis (NCT05642468) | Albireo, an Ipsen Company | 2023-01-09 |
| An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia (NCT05426733) | Albireo, an Ipsen Company | 2022-07-05 |
| Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome (NCT05035030) | Albireo, an Ipsen Company | 2021-09-03 |
| Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD) (NCT04336722) | Albireo, an Ipsen Company | 2020-07-08 |
| Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC (NCT03659916) | Albireo, an Ipsen Company | 2018-09-28 |
Track Albireo, an Ipsen Company automatically
Every clearance here is in the API, with alerts when new ones post.